Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biotricity, Inc. stock logo
BTCY
Biotricity
$0.63
+16.7%
$0.44
$0.19
$0.83
$15.71M1.1238,604 shs49,487 shs
Daxor Corporation stock logo
DXR
Daxor
$10.60
-0.1%
$9.63
$6.55
$11.38
$51.32M-0.1377,880 shs5,434 shs
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
$1.02
+4.4%
$1.69
$0.83
$3.72
$49.15M1.661.20 million shs813,382 shs
Nephros Inc. stock logo
NEPH
Nephros
$4.25
+6.3%
$3.78
$1.36
$5.00
$42.40M1.1142,904 shs60,185 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biotricity, Inc. stock logo
BTCY
Biotricity
+16.74%+42.88%+66.55%+30.84%+46.33%
Daxor Corporation stock logo
DXR
Daxor
-0.09%+5.79%+13.86%+38.38%+21.70%
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
+4.36%+6.10%-37.80%-39.64%-54.26%
Nephros Inc. stock logo
NEPH
Nephros
+6.25%+8.97%+23.19%+96.76%+128.49%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biotricity, Inc. stock logo
BTCY
Biotricity
N/AN/AN/AN/AN/AN/AN/AN/A
Daxor Corporation stock logo
DXR
Daxor
4.0777 of 5 stars
3.55.00.00.02.51.70.0
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
2.0394 of 5 stars
3.52.00.00.02.21.70.0
Nephros Inc. stock logo
NEPH
Nephros
2.4437 of 5 stars
3.53.00.00.03.40.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biotricity, Inc. stock logo
BTCY
Biotricity
2.00
HoldN/AN/A
Daxor Corporation stock logo
DXR
Daxor
3.00
Buy$25.00135.85% Upside
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
3.00
Buy$8.00684.31% Upside
Nephros Inc. stock logo
NEPH
Nephros
3.00
Buy$5.5029.41% Upside

Current Analyst Ratings Breakdown

Latest BTCY, DXR, GUTS, and NEPH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2025
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $6.00
8/8/2025
Nephros Inc. stock logo
NEPH
Nephros
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$4.50 ➝ $6.00
(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biotricity, Inc. stock logo
BTCY
Biotricity
$12.06M1.30N/AN/A($1.30) per share-0.48
Daxor Corporation stock logo
DXR
Daxor
N/AN/AN/AN/AN/AN/A
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
$90K569.95N/AN/A($0.36) per share-2.83
Nephros Inc. stock logo
NEPH
Nephros
$14.16M3.18$0.02 per share199.89$0.91 per share4.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biotricity, Inc. stock logo
BTCY
Biotricity
-$14.09M-$0.67N/AN/A-80.42%N/A-188.47%N/A
Daxor Corporation stock logo
DXR
Daxor
N/AN/A0.00N/AN/AN/AN/AN/A
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
-$68.69M-$1.85N/AN/AN/A-73,864.52%-584.35%-102.88%N/A
Nephros Inc. stock logo
NEPH
Nephros
$70K$0.1235.42N/A7.95%14.89%11.64%N/A

Latest BTCY, DXR, GUTS, and NEPH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
-$0.37-$0.53-$0.16-$0.57N/AN/A
8/7/2025Q2 2025
Nephros Inc. stock logo
NEPH
Nephros
-$0.0250$0.02+$0.0450$0.02$3.60 million$4.40 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biotricity, Inc. stock logo
BTCY
Biotricity
N/AN/AN/AN/AN/A
Daxor Corporation stock logo
DXR
Daxor
N/AN/AN/AN/AN/A
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
N/AN/AN/AN/AN/A
Nephros Inc. stock logo
NEPH
Nephros
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biotricity, Inc. stock logo
BTCY
Biotricity
N/A
0.23
0.10
Daxor Corporation stock logo
DXR
Daxor
N/AN/AN/A
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
4.61
1.22
2.50
Nephros Inc. stock logo
NEPH
Nephros
N/A
5.41
4.64

Institutional Ownership

CompanyInstitutional Ownership
Biotricity, Inc. stock logo
BTCY
Biotricity
3.89%
Daxor Corporation stock logo
DXR
Daxor
1.34%
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
N/A
Nephros Inc. stock logo
NEPH
Nephros
41.10%

Insider Ownership

CompanyInsider Ownership
Biotricity, Inc. stock logo
BTCY
Biotricity
10.10%
Daxor Corporation stock logo
DXR
Daxor
59.50%
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
27.00%
Nephros Inc. stock logo
NEPH
Nephros
6.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biotricity, Inc. stock logo
BTCY
Biotricity
4024.91 million22.08 millionOptionable
Daxor Corporation stock logo
DXR
Daxor
374.84 million1.96 millionNot Optionable
Fractyl Health, Inc. stock logo
GUTS
Fractyl Health
10250.29 million36.71 millionN/A
Nephros Inc. stock logo
NEPH
Nephros
3010.60 million9.89 millionNot Optionable

Recent News About These Companies

Nephros Second Quarter 2025 Earnings: Beats Expectations
Nephros Announces Strong Second Quarter Financial Results
Nephros to Host Analyst and Investor Virtual Event
Nephros Launches New S100 In-Line Microfilter
Nephros Full Year 2024 Earnings: Beats Expectations

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biotricity stock logo

Biotricity NASDAQ:BTCY

$0.63 +0.09 (+16.74%)
As of 08/15/2025 03:34 PM Eastern

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

Daxor stock logo

Daxor NASDAQ:DXR

$10.60 -0.01 (-0.09%)
As of 08/15/2025 03:56 PM Eastern

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

Fractyl Health stock logo

Fractyl Health NASDAQ:GUTS

$1.02 +0.04 (+4.36%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$1.02 +0.00 (+0.39%)
As of 08/15/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Nephros stock logo

Nephros NASDAQ:NEPH

$4.25 +0.25 (+6.25%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$4.27 +0.02 (+0.47%)
As of 08/15/2025 07:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.